AlphAIAlphAI — Financial news for AI agents
FinancialContentMAY 72 min read$SST

System1, Inc. Class A Common Stock (NYSE:SST) Stock Quote

This page provides a stock quote and recent news for System1, Inc. Class A Common Stock (NYSE:SST), showing its current trading price, performance metrics, and various news headlines. It includes financial results announcements, conference participations, and information regarding a reverse stock split. The article also features a FAQ section about the company's public trading status and market capitalization.

Original reporting
FinancialContent
Published May 7, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 7, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
System1, Inc. Class A Common Stock (NYSE:SST) Stock Quote — source image
Source · FinancialContent
Decision brief

The 30-second read

$SSTNeutralLow
01

Why it matters

These corporate activities suggest a focus on shareholder value and capital restructuring, which may influence investor perception over the medium term.

02

Market read

The news is relevant to current and potential investors in SST, but has limited immediate trading implications.

03

What to watch

Potential future regulatory changes or market conditions not covered in the news could impact the stock.

Relevance 6/10Timing: Long-term

Background

System1, Inc. has recently reported financial results, participated in investor conferences, and announced a reverse stock split, indicating corporate restructuring and strategic positioning.

Company-level read

Ticker impact

$SSTNeutralMedium confidence
Context

The news pertains directly to System1, Inc. (NYSE:SST), including recent financial results, corporate actions, and market status.

Expected impact

Limited immediate impact; potential for slight positive bias if financial results are favorable, but overall neutral due to lack of strong catalysts.

Evidence & confidence

The news covers standard corporate updates without significant surprises or negative signals, suggesting minimal short-term volatility.

Market effects

Sector

The earnings and corporate actions may influence investor sentiment within the financial markets sector, but no broad sector shifts are indicated.

Regional

Limited regional impact; news pertains specifically to a U.S.-listed company.

Global

Minimal global relevance given the company's size and the nature of the news.

Counterpoint

What could challenge this read

If upcoming financial results are worse than anticipated, the stock could decline despite current neutrality.

Key entities

  • Company
    System1, Inc.

    A publicly traded company listed on NYSE, involved in digital marketing and advertising solutions.

Read at source← All news

Related articles

AUG 5
$SSTMed

System1 Announces Second Quarter 2026 Financial Results and Launch of New Agentic Products

System1, Inc. (SST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 System1 Announces Second Quarter 2026 Financial Results and Launch of New Agentic Products • Revenue of $30.2 million • GAAP Gross Profit of $24.3 million, margin of 80% • Adjusted Gross Profit of $25.5 million, margin of 85% • GAAP Net Loss of $15.3 million • Adjust

SEC EDGAR 8-K6 min
OCT 24
$NVDAMed

Nvidia's AI Financing Faces First Big Market Test

Nvidia is financing AI projects, offering $500B in off-balance-sheet guarantees. CEO Jensen Huang aims to fund demand, citing strong interest. Nvidia's revenue hit $216B in FY2024, with $70B in free cash flow. Partners like CoreWeave face credit tightening, with shares down 30%. Nvidia's stock fell 7.6% in October, raising concerns about demand meeting expectations.

briefs.co2 min
OCT 24
$AZNHigh

AZ Combo Extends Lung Cancer Survival

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.

briefs.co2 min
OCT 24
$MRNAHigh

New Personalised mRNA Therapy Improves Melanoma Outcomes: ESMO 2026

A Phase III trial showed that intismeran autogene, a personalized mRNA therapy, combined with pembrolizumab, reduced the risk of death or recurrence by 42% in high-risk melanoma patients. The study, presented at ESMO 2026, enrolled 1,137 patients and demonstrated improved recurrence-free and distant metastasis-free survival. Despite the positive clinical results, a data leak caused shares of manufacturers Moderna and Merck to fall.

emjreviews.com3 min
OCT 24
$BIVIMedAI 8/10

From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television

New to The Street Show #777 features executives from Stewards Investment Capital, BioVie (NASDAQ:BIVI), FreeCast (NASDAQ:CAST), and American Fusion (OTCQB:AMFN). BioVie reports positive long COVID and Parkinson's trial results. FreeCast discusses its media monetization technology. American Fusion presents its fusion power technology. The show airs on Bloomberg Television and YouTube.

finanznachrichten.de2 min
OCT 24
$AZNHigh

AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

AstraZeneca's VOLGA Phase III trial showed that perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced the risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer patients. The combination therapy demonstrated statistically significant improvements in event-free survival and overall survival compared to the standard of care. According to AstraZeneca, more than three quarters of patients were still alive two years after treatment.

finanznachrichten.de3 min